BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Golforoush PA, Narasimhan P, Chaves-Guerrero PP, Lawrence E, Newton G, Yan R, Harding SE, Perrior T, Chapman KL, Schneider MD. Selective protection of human cardiomyocytes from anthracycline cardiotoxicity by small molecule inhibitors of MAP4K4. Sci Rep 2020;10:12060. [PMID: 32694738 DOI: 10.1038/s41598-020-68907-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Fuller SJ, Edmunds NS, McGuffin LJ, Hardyman MA, Cull JJ, Alharbi HO, Meijles DN, Sugden PH, Clerk A. MAP4K4 expression in cardiomyocytes: multiple isoforms, multiple phosphorylations and interactions with striatins. Biochem J 2021;478:2121-43. [PMID: 34032269 DOI: 10.1042/BCJ20210003] [Reference Citation Analysis]
2 Berecz T, Yiu A, Vittay O, Orsolits B, Mioulane M, Dos Remedios CG, Ketteler R, Merkely B, Apáti Á, Harding SE, Hellen N, Foldes G. Transcriptional co-activators YAP1-TAZ of Hippo signalling in doxorubicin-induced cardiomyopathy. ESC Heart Fail 2021. [PMID: 34931757 DOI: 10.1002/ehf2.13756] [Reference Citation Analysis]
3 Borges GSM, Lages EB, Sicard P, Ferreira LAM, Richard S. Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies. Front Cardiovasc Med 2021;8:690533. [PMID: 34277738 DOI: 10.3389/fcvm.2021.690533] [Reference Citation Analysis]
4 Wu BB, Leung KT, Poon EN. Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity. Int J Mol Sci 2022;23:1912. [PMID: 35163838 DOI: 10.3390/ijms23031912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]